Value Investor
Start free

Myriad Genetics

MYGN on Nasdaq. Myriad Genetics sells molecular tests to patients and providers. Market value $438m.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

Should I look at this?

Not a fit for our list right now

Why it could be worth it

What to watch out for

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
-1.8%low

For every $100 of what the whole company costs, it produced $-1.78 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
-21.2%five-year median

Each dollar kept in the business earns -21 cents a year. Above 10 is good.

Quality score: 43 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$4.28 a share, 56% above its 1-year low

Over the past year the price has ranged from $2.74 to $8.59.

Pays no dividend

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

0.0
-0.2
-0.2
-0.0
-0.0
-0.0
2021202220232024202512 monthsto Jun '26

Spare cash swings from quarter to quarter here: a shortfall of $7 million in the past 12 months, a shortfall of $14 million in the year to December 2025.

Revenue
$691m$678m$753m$838m$825m
Operating margin
-27.6%-20.7%-34.2%-14.7%-47.0%
Debt to equity
0.000.000.050.060.33
Shares outstanding
0.08bn0.08bn0.09bn0.09bn0.10bn

Health checks

  • Free cash flow positive1 of 5 years
  • Accounting looks honest (Beneish)Nothing unusual
  • Financial strength (Piotroski)5 of 9
  • Profit backed by cash (accruals)No
  • Debt0.33× equity
  • Revenue growth, five yearsSlow, 4.8% a year
  • Buying back its own sharesNo, 18% more shares since 2021

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $191 million last quarter, down 11% on a year ago.
  • A loss of $43 million, compared with a loss of $331 million a year ago.
  • It loses 12 cents on each $1 of sales, compared with 50 cents a year earlier.
  • Over the past 12 months it spent $7 million more cash than it brought in, compared with $38 million a year earlier.
  • 2% more shares than a year ago. Each share owns a bit less of the company.
  • Debt is $6 million more than cash. A year ago it had $15 million more cash than debt.
  • Sales grew on a year ago in 1 of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$213m
December 2024$211m
March 2025$196m
June 2025$213m
September 2025$206m
December 2025$210m
March 2026$200m
June 2026$191m
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024-$22m
December 2024-$43m
March 2025-$100,000
June 2025-$331m
September 2025-$27m
December 2025-$8m
March 2026-$34m
June 2026-$43m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
24 February 2026
Next quarterly (estimated, 10-Q)
30 October 2026

Who owns it

1 long-term investor we follow owns it, unchanged from 1 last quarter. 197 funds in all.

Jun '25
Dec '25
Jun '26

Sold out this quarter

Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

7 investors own more than 5%.

  • BlackRock Portfolio Management LLC
    Passive investor
    10.4%
    Since 31 August 2026
  • BlackRock, Inc.
    Passive investor
    8.5%−6.8 pts
    Since 31 March 2026
  • Millennium Management LLC
    Passive investor
    at least 7.2%+2.1 pts
    (filed with 3 related holders)
    Since 31 December 2025
  • Vestal Point Capital, LP
    Passive investor
    at least 6.1%
    (filed with 1 related holder)
    Since 30 June 2026
  • Wellington Management Company LLP
    Passive investor
    6.0%
    Since 31 December 2024
  • STATE STREET CORPORATION
    Passive investor
    5.3%+0.6 pts
    Since 30 June 2026
  • Camber Capital Management LP
    Passive investor
    at least 3.4%
    (filed with 1 related holder)
    Since 31 December 2024
  • Barclays PLC
    Passive investor
    Sold down below 5%
    Since 30 September 2025
  • Sold down below 5%
    Since 30 June 2025
  • Sold down below 5%
    Since 30 June 2026
  • The Vanguard Group
    Passive investor
    Sold down below 5%
    Since 13 March 2026
  • Sold down below 5%
    Since 30 June 2025

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 3 insiders bought $722,223 of shares on the open market. 1 sold $66,900, $66,900 of it under preset trading plans.

  • Kumar Rashmi
    Director
    Sold
    under a preset trading plan
    Date
    8 June 2026
    Shares
    15,000
    Price
    $4.46
    Value
    $66,900
  • Bisaro Paul
    Director
    Bought
    Date
    14 May 2026
    Shares
    7,500
    Price
    $3.69
    Value
    $27,675
  • Raha Samraat S.
    President and CEO, Director
    Bought
    Date
    9 March 2026
    Shares
    40,000
    Price
    $5.00
    Value
    $200,000
  • Phanstiel S. Louise
    Director
    Bought
    Date
    27 February 2026
    Shares
    48,000
    Price
    $4.66
    Value
    $223,680
  • Phanstiel S. Louise
    Director
    Bought
    Date
    26 February 2026
    Shares
    50,407
    Price
    $4.80
    Value
    $241,954
  • Phanstiel S. Louise
    Director
    Bought
    Date
    25 February 2026
    Shares
    6,100
    Price
    $4.74
    Value
    $28,914

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 24 Feb 2026, plus the 10-Q filed 31 Jul 2026 and 5 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.